Contract research organizations (CROs) have transformed the way research are conducted by several pharmaceutical, biotechnology, and medical devices companies in ways more than one. These organizations offer a variety of services such as biopharmaceutical development, clinical trials conduct and other endeavors, drug discovery activities, product commercialization, assay development, and pharmacovigilance. The intensifying demand for new therapies and devices has mounted pressures on research and development (R&D) budgets of these organizations.